Drug Database
SI

simvastatin (simvastatin, Hanmi / simvastatin CR / Simvast CR)

✓ Approved

Hanmi Pharmaceutical · HMGCR · 小分子

什么是 simvastatin?

simvastatin 是一种小分子,由Hanmi Pharmaceutical研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名simvastatin, Hanmi, simvastatin CR, Simvast CR
公司Hanmi Pharmaceutical
药物类别小分子
分子靶点HMGCR
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

simvastatin 作用于 1 个分子靶点:

HMGCR3-hydroxy-3-methylglutaryl-CoA reductase (LDLCQ3, LGMDR28)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

simvastatin 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Metabolism and nutrition disordersHyperlipidaemia✓ Approved

相关研究文献

PubMedPharmacology research & perspectives2026-11-16

Simvastatin Alleviation of Trimethyltin-Induced Hippocampal and Behavioral Impairments via Improvement of Antioxidants, Mitochondrial Health, and Energy Homeostasis.

Salari Adel A, Taheri Mahdieh M, Khalili Mohsen M, Roghani Mehrdad M

Mitochondrial dysfunction and antioxidant deficiency are key contributors to the pathogenesis of Alzheimer's disease (AD). Trimethyltin (TMT) induces selective hippocampal damage associated with redox disequilibrium, neuroinflammatory responses, mitochondrial dysfunction, and impaired energy homeostasis, leading to cognitive decline. The present study evaluated whether simvastatin as a lipid-lowering and protective medicine could mitigate TMT-induced behavioral abnormalities by improving hippocampal antioxidant status, mitochondrial integrity, and energy homeostasis. Rats were assigned to control, control + simvastatin (30 mg/kg), TMT, TMT + simvastatin (10 mg/kg), and TMT + simvastatin (30 mg/kg) groups. TMT was injected IP (once, 8 mg/kg) to instigate neurotoxicity. Following three weeks of treatment, locomotor activity and conditioned learning and memory deficits were analyzed using open-field and passive avoidance tests, respectively. Besides, hippocampal levels or activity of nitrite, glutathione (GSH), glutathione peroxidase (GPx), myeloperoxidase (MPO), and β-site APP-cleaving enzyme 1 (BACE1), mitochondrial membrane potential (MMP), and AMP-activated protein kinase (AMPK) were measured. Simvastatin treatment (30 mg/kg) was associated with higher latency in the passive avoidance test and longer rearing in the open field test in TMT-intoxicated rats. Additionally, simvastatin improved hippocampal GSH, GPx, MMP, and AMPK and mitigated MPO activity relative to the TMT group but did not significantly affect nitrite or BACE-1 activity. Collectively, simvastatin mitigated TMT-induced neurobehavioral impairment, partly through restoration of antioxidants and mitochondrial health in association with AMPK.

PMID 43035405
阅读全文 →
PubMedJournal of drug targeting2026-11-16

Comparative Evaluation of Intranasal Simvastatin-Loaded Transbilosomes Versus Oral Simvastatin Suspension in Attenuating Heart Failure in Rat Models Induced by Doxorubicin and Ischemia/Reperfusion.

Rofaiel Wahba Rofaiel Mariam M, Mahmoud Dina M DM, Baali Fahad H FH, Belal Amany A et al.

Simvastatin (SMS) has profound lipid-independent "pleiotropic" effects that benefit heart failure (HF), but its poor solubility and bioavailability limit its efficacy. This study developed nasal simvastatin-loaded transbilosomes (SLT) to improve drug solubility and bioavailability and mitigate HF. To develop an optimal SLT formulation, the Box-Behnken design was employed. The effectiveness of the nasal SLT was evaluated in vivo using rat models of HF induced by either doxorubicin or ischemia/reperfusion. Relative to free SMS, the optimal SLT achieved a release increase of 3.81-fold, increased bioavailability by 6.35-fold, enhanced permeation by 7.46-fold, and increased the cardiac accumulation by 1.96-fold. Compared to the oral SMS group, the nasal SLT group exhibited significantly lower levels of triglycerides, cholesterol, LDL, CK-MB, LDH, troponin I, NT-proBNP, NO, MDA, and heart rate, being 1.49-fold, 1.47-fold, 1.40-fold, 1.48-fold, 1.42-fold, 1.59-fold, 1.42-fold, 2.0-fold, 1.90-fold, and 1.99-fold lower, respectively. Conversely, HDL, GSH, SOD, ejection fraction, and fractional shortening increased by 1.5-fold, 1.95-fold, 1.48-fold, 1.48-fold, and 1.42-fold, respectively. Histopathology examination validated the efficacy of the nasal SLT formulation. While these findings represent nasal SLT as a promising insight in alleviating HF, future work is recommended to fully elucidate the distinct contribution of isolated vehicle and route controls.

PMID 43039854
阅读全文 →
PubMedMaterials today. Bio2026-11-15

Does simvastatin-adenosine-loaded nanostructured lipid carrier counteract the pathophysiology of diabetic wounds? Evidence from 3D skin models.

Daré Regina Gomes RG, Di Stolfo Luigi L, de Almeida Mauro Sousa MS, Petri-Fink Alke A et al.

Chronic wounds, such as diabetic foot ulcers, represent a clinical challenge due to impaired healing processes. Traditional two-dimensional cell cultures fail to replicate the complexity of human skin, limiting therapeutic predictability. We previously developed nanostructured lipid carrier co-loaded with simvastatin and adenosine (NLC-SA), which enhanced keratinocyte proliferation and skin drug retention. Herein, we advanced to physiologically relevant three-dimensional human skin equivalents (HSEs) and reconstructed human epidermis (RHEs) to model chronic diabetic wounds and evaluate the therapeutic potential of NLC-SA. RHE generated from primary human keratinocytes (NHEK) exhibited superior epidermal architecture and barrier properties compared with HaCat-based constructs and was selected for subsequent studies. Full-thickness HSEs were developed using NHEK and primary human dermal fibroblasts (NHDF). Chronic wound-like conditions were induced by exposure to high glucose and TNF-α for five days, which reduced tissue viability, increased inflammatory mediators (IL-1α and IL-8) and expression of the corresponding inflammatory genes (IL1A and CXCL8), reduced expression of the oxidative stress-responsive gene HMOX1, disrupted epidermal differentiation (LOR and FLG downregulation), and decreased VEGF secretion. NLC-SA treatment exerted multifaceted therapeutic effects. In RHE, treatment improved tissue viability, downregulated IL1A and CXCL8 mRNA expression, and increased HMOX1 and LOR mRNA expression. In both RHE and HSE models, NLC-SA reduced IL-1α and IL-8 secretion and enhanced VEGF release. Pro-angiogenic activity was further supported by the chick chorioallantoic membrane assay, in which NLC-SA increased relative vessel growth and total vessel length. In conclusion, NLC-SA demonstrated significant cytoprotective, anti-inflammatory, and pro-angiogenic properties in a human-relevant 3D chronic wound model, providing a rationale for further evaluation of its therapeutic efficacy in diabetic wound models in vivo.

PMID 43034856
阅读全文 →
PubMedBrain communications2026-11-15

Pharmacological treatments in disorders of consciousness.

Saleh Christian C, Seyfzadeh Fatemeh F, Szymkowicz Emilie E, Alnagger Naji N et al.

Disorders of consciousness (DoC) are among the most severe and devastating neurological conditions. The poorly understood underlying pathophysiology of DoC renders the search for adequate treatment options particularly difficult. The aim of this narrative review is to provide an overview of currently available pharmacological treatments, report the limitations of current research and discuss future directions, notably potential new treatments, advances in modelling approaches, potential mechanisms of action and the development of a standardized registry. We review pharmacological treatments that promote the recovery of consciousness in patients with DoC acting on dopaminergic (amantadine, levodopa, apomorphine, methylphenidate, bromocriptine, modafinil and selegiline) and GABAergic (zolpidem, baclofen and midazolam) pathways, as well as other pharmacological treatments (tricyclic antidepressants, anticonvulsants and simvastatin) and the combination of different treatments. The literature includes a limited number of randomized controlled trials (RCTs) alongside a large body of retrospective studies and case reports, which are classified as class IV evidence. Reported improvements in arousal or responsiveness are inconsistent, reflecting marked heterogeneity in patient populations, dosing regimens and outcome measures. Risk-of-bias assessment indicated that 12 of 22 RCTs (∼55%) exhibit some concerns or a high risk of bias. Multiple correspondence analysis yielded a descriptive mapping of RCT characteristics, demonstrating how pharmacological trials in DoC are grouped. Although mechanistic hypotheses converge on dopaminergic, GABAergic and thalamocortical modulation, the current literature on pharmacological treatments in DoC remains poorly reproducible. Given the significant methodological variability (e.g. study design, patient characteristics and outcome measures) across studies, current evidence does not allow firm conclusions regarding the most effective consciousness-enhancing pharmacological treatments in DoC. To make informed decisions in terms of pharmacological treatments and move towards personalized care for patients with DoC, rigorously designed multicentre controlled trials with harmonized outcome measures conducted with mechanistic and computational approaches are required. This can be achieved through an international registry to standardize data collection and improve reproducibility and replicability.

PMID 43032840
阅读全文 →
PubMedInternational journal of molecular sciences2026-11-14

A TLR4-Associated Microglia-Endothelial Inflammatory Axis in Drug-Resistant Temporal Lobe Epilepsy: Integrated Transcriptomic and Genetic Evidence.

Liu Zhenglin Z, Yin Jian J

Microglia-driven neuroinflammation contributes to epileptogenesis and drug resistance in temporal lobe epilepsy (TLE), but the cellular organization of the neuroinflammatory hub and its coupling to the cerebrovascular endothelium remain unresolved. We performed a retrospective secondary analysis of publicly available datasets, integrating paired hippocampal bulk transcriptomics (GSE134697), an integrated temporal-lobe single-cell/nucleus RNA sequencing (sc/snRNA-seq) atlas (9 patients with drug-resistant TLE and 4 controls), two-sample Mendelian randomization (MR) and summary-based Mendelian randomization (SMR), and independent hippocampal (n = 77) and peripheral blood (n = 141) cohorts. Five candidate neuroimmune hub genes (TGFB1, ICAM1, TLR4, TLR2 and CCL2) were prioritized using a prespecified, threshold-dependent workflow and mapped to a microglia-cerebrovascular endothelium-peripheral myeloid cell axis. sc/snRNA-seq identified an activated endothelial subpopulation, detected only in TLE samples, and expansion of a microglial compartment with disease-associated microglia (DAM)-like features; CellChat and MultiNicheNet prioritized microglia-derived SPP1, C1QA and MIF as candidate mediators of endothelial inflammatory activation via S1PR1/ITGB1, CD93 and CD74. Plasma kynurenine showed a nominally significant association with focal epilepsy in MR (inverse-variance weighted [IVW] OR = 1.96, 95% CI 1.10-3.52, p = 0.024), whereas SMR did not detect genetically predicted effects of TLR4 or TLR2 expression on focal epilepsy risk; these findings do not establish an acquired disease mechanism. A TGFB1 + TLR4 two-gene signature showed exploratory discrimination in an independent hippocampal cohort (area under the receiver operating characteristic curve [AUC] = 0.868), and blood TLR4 was selectively elevated in drug-naïve newly diagnosed patients (AUC = 0.684). Targeted gene set enrichment analysis (GSEA) and molecular docking nominated simvastatin as a repurposing candidate predicted computationally to interact with MD-2; this prediction has not been functionally validated. This multi-cohort study identifies a TLR4-associated microglia-endothelial inflammatory axis in drug-resistant TLE and generates hypotheses for prospective biomarker studies and experimental drug-repurposing research.

PMID 43028205
阅读全文 →
PubMedAustralian endodontic journal : the journal of the Australian Society of Endodontology Inc2026-11-11

Comparative Evaluation of Bone Regeneration With L-PRF, Amniotic Membrane, Simvastatin Using CBCT After Endodontic Surgery: Randomized Clinical Trial.

Singh Niharika N, Verma Promila P, Tikku A P AP, Yadav Rakesh Kumar RK et al.

The present study evaluates and compares the effectiveness of Leucocyte-platelet rich fibrin (L-PRF), Simvastatin (SIM) and amniotic membrane (AM) in bone regeneration of periapical defects. A total of 42 patients fulfilling all the inclusion criteria were enrolled for the study and randomly divided into three groups (n = 14) by allocation concealment method. Group I (L-PRF = 14), Group II (SIM = 14), Group III (AM = 14). A total of 36 patients (12 in each group) were statistically analysed for results after excluding the data lost to follow-up in all three groups. Intragroup analysis of CBCT-Periapical Index (PAI) scores at 6th and 12th month revealed considerable change in the SIM (p = 0.053 and 0.231, respectively) compared to L-PRF group (p = 0.135 and 0.406, respectively) and AM (0.531 and 0.494, respectively). When used as a bone graft material, simvastatin showed numerically higher but not statistically significant results (p > 0.05). Trial Registration: The study was registered to the Clinical Trials Registry-India (CTRI), with a registration number CTRI/2022/08/044782, before the commencement of the study.

PMID 43015063
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多simvastatin